Ladenburg Thalmann Financial Services’s Aimmune Therapeutics AIMT Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$53K	Buy	1,579 +491	+45%	+$13.7K	﹤0.01%	3492
2019 Q3	$24K	Buy	1,088 +731	+205%	+$14.9K	﹤0.01%	3936
2019 Q2	$7K	Buy	357 +1	+0.3%	+$21	﹤0.01%	4608
2019 Q1	$9K	Buy	356 +34	+11%	+$800	﹤0.01%	4451
2018 Q4	$8K	Buy	322 +287	+820%	+$7.43K	﹤0.01%	4421
2018 Q3	$1K	Buy	35 +2	+6%	+$57	﹤0.01%	5083
2018 Q2	$1K	Hold	33	–	–	﹤0.01%	5050
2018 Q1	$1K	Hold	33	–	–	﹤0.01%	5050
2017 Q4	$1K	Hold	33	–	–	﹤0.01%	4970
2017 Q3	$1K	Hold	33	–	–	﹤0.01%	4871
2017 Q2	$1K	Hold	33	–	–	﹤0.01%	4809
2017 Q1	$1K	Hold	33	–	–	﹤0.01%	4785
2016 Q4	$1K	Hold	33	–	–	﹤0.01%	4762
2016 Q3	$0	Hold	33	–	–	﹤0.01%	4924
2016 Q2	$0	Hold	33	–	–	﹤0.01%	4893
2016 Q1	$0	Buy	+33	New	+$515	﹤0.01%	4870

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ladenburg Thalmann Financial Services's AIMT Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Aimmune Therapeutics (AIMT) stake by 45% in Q4 2019, buying an estimated $13.7K and bringing the position to 1,579 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #3492.

Ladenburg Thalmann Financial Services first reported a position in AIMT in Q1 2016 and has held it in 16 quarters since. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

Ladenburg Thalmann Financial Services held 1,579 shares of Aimmune Therapeutics worth $53K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 491 Aimmune Therapeutics shares in Q4 2019, an estimated $13.7K.
Aimmune Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3492 holding.
Ladenburg Thalmann Financial Services first reported a position in Aimmune Therapeutics in Q1 2016 and has held it in 16 quarters since.
155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.